Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giulia Benevolo

Showing results (111-120 of 123) with videos related to

Pageof 13
Sort By:
Blood Advances|March 19, 2026
Quantitative MYD88 L265P and flow cytometry levels for outcome determination in IgM gammopathies: the SAL-TO studyIrene Dogliotti, Cristina Jiménez, Veronica Peri, et al.
Blood|December 24, 2019
Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control studyValerio De Stefano, Arianna Ghirardi, Arianna Masciulli, et al.
American Journal of Hematology|December 10, 2019
Second cancers in MPN: Survival analysis from an international studyMonia Marchetti, Arianna Ghirardi, Arianna Masciulli, et al.
Blood Cancer Journal|May 3, 2023
Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinibFrancesca Palandri, Elena M Elli, Giuseppe Auteri, et al.
Hematological Oncology|March 25, 2026
Clinical Outcomes of Ruxolitinib Treatment in Patients With IPSS Intermediate-1-Risk Myelofibrosis: Interim Analysis From an Italian, Prospective Study (ROMEI)Paola Guglielmelli, Massimo Breccia, Francesco Mendicino, et al.
Cancer|March 20, 2025
Dosing and clinical outcomes of ruxolitinib in patients with myelofibrosis in a real-world setting: Interim results of the Italian observational study (ROMEI)Massimo Breccia, Francesca Palandri, Maurizio Martelli, et al.
Leukemia|January 8, 2021
High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinibTiziano Barbui, Alessandro Maria Vannucchi, Alberto Alvarez-Larran, et al.
Blood Cancer Journal|February 10, 2021
Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19Tiziano Barbui, Valerio De Stefano, Alberto Alvarez-Larran, et al.
Blood Cancer Journal|June 17, 2021
Long-term follow-up of recovered MPN patients with COVID-19Tiziano Barbui, Alessandra Iurlo, Arianna Masciulli, et al.
American Journal of Hematology|September 16, 2022
Determinants of early triage for hospitalization in myeloproliferative neoplasm (MPN) patients with COVID-19Tiziano Barbui, Alessandra Carobbio, Arianna Ghirardi, et al.
Pageof 13

Showing results (111-120 of 123) with videos related to

Sort By:
Pageof 13
Blood Advances|March 19, 2026
Quantitative MYD88 L265P and flow cytometry levels for outcome determination in IgM gammopathies: the SAL-TO studyIrene Dogliotti, Cristina Jiménez, Veronica Peri, et al.
Blood|December 24, 2019
Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control studyValerio De Stefano, Arianna Ghirardi, Arianna Masciulli, et al.
American Journal of Hematology|December 10, 2019
Second cancers in MPN: Survival analysis from an international studyMonia Marchetti, Arianna Ghirardi, Arianna Masciulli, et al.
Blood Cancer Journal|May 3, 2023
Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinibFrancesca Palandri, Elena M Elli, Giuseppe Auteri, et al.
Hematological Oncology|March 25, 2026
Clinical Outcomes of Ruxolitinib Treatment in Patients With IPSS Intermediate-1-Risk Myelofibrosis: Interim Analysis From an Italian, Prospective Study (ROMEI)Paola Guglielmelli, Massimo Breccia, Francesco Mendicino, et al.
Cancer|March 20, 2025
Dosing and clinical outcomes of ruxolitinib in patients with myelofibrosis in a real-world setting: Interim results of the Italian observational study (ROMEI)Massimo Breccia, Francesca Palandri, Maurizio Martelli, et al.
Leukemia|January 8, 2021
High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinibTiziano Barbui, Alessandro Maria Vannucchi, Alberto Alvarez-Larran, et al.
Blood Cancer Journal|February 10, 2021
Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19Tiziano Barbui, Valerio De Stefano, Alberto Alvarez-Larran, et al.
Blood Cancer Journal|June 17, 2021
Long-term follow-up of recovered MPN patients with COVID-19Tiziano Barbui, Alessandra Iurlo, Arianna Masciulli, et al.
American Journal of Hematology|September 16, 2022
Determinants of early triage for hospitalization in myeloproliferative neoplasm (MPN) patients with COVID-19Tiziano Barbui, Alessandra Carobbio, Arianna Ghirardi, et al.
Pageof 13